A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Molecular correlates (EGFR status) and plasma VEGF levels associated with a phase II study of bevacizumab plus erlotinib (BE) for patients with recurrent ovarian cancer (OC) and fallopian tube (FT) cancer
Halla S. Nimeiri,Leonardo Faoro,Amit M. Oza,Robert J. Morgan,David R. Gandara,Varalakshmi Janamanchi,Ravi Salgia,Walter M. Stadler,E. E. Vokes,Gini F. Fleming +9 more
TL;DR: This work examined the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) factors for prognostic value in the setting of treatment with BE and found that these factors may correlate with poor prognosis.
Journal ArticleDOI
Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.
Yeh Chen Lee,Nazlin Jivraj,Catherine A. O’Brien,Jenny Lau,Tanya Chawla,Eran Shlomovitz,Sarah Buchanan,Jennifer Croke,Johane P. Allard,Preeti Dhar,Stephane Laframboise,Sarah E. Ferguson,Neesha C. Dhani,Marcus O. Butler,Pamela Ng,Terri Stuart-McEwan,Pamela Savage,Lisa Tinker,Amit M. Oza,Stephanie Lheureux +19 more
TL;DR: An inter-professional MBO management program is implemented incorporating a nurse-led ambulatory symptom management algorithm and multidisciplinary care conferences (MCC) as hallmarks of this program.
Journal ArticleDOI
Final results of a phase I study of adjuvant chemoradiation for gastric adenocarcinoma with infusional 5-fluorouracil and bi-weekly cisplatin.
Z. Kassam,Helen Mackay,C. Buckley,J.D. Brierley,John Kim,L.L. Siu,Carol J. Swallow,Sharon Fung,Amit M. Oza,Jolie Ringash +9 more
TL;DR: The maximum tolerated dose (MTD) of 2-weekly cisplatin, infusional 5-FU and concurrent conformal radiotherapy for resected gastric cancer was assessed in this phase I study.
Phase i/ii dose-escalation trial of patupilone every 3 weeks in patients (pts) with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer
Willem M. Smit,A. H. Honkoop,Stanislav Spanik,Maria Wagnerova,Amit M. Oza,Stan B. Kaye,A. Johri,Sara Zaknoen,W. W. Huinink +8 more
Journal ArticleDOI
ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
Sw. Banerjee,Bradley J. Monk,Els Van Nieuwenhuysen,Kathleen N. Moore,Ana Oaknin,Michel Fabbro,Nicoletta Colombo,David M. O'Malley,Robert E. Coleman,Amit M. Oza,Jonathan A. Pachter,Gloria Patrick,Louis Denis,Lorna Leonard,Rachel N. Grisham +14 more
TL;DR: In this proof-of-concept study, durable objective responses have been reported in recurrent LGSOC pts, including pts who have had a prior MEK inhibitor and the combination of VS-6766 + defactinib has received FDA Breakthrough Therapy Designation for recurrent L GSOC.